1 |
张国宁, 侯波, 单连成, 等. 中老年人群髋部骨折发病率调查:上海市长宁区数据分析[J]. 中国组织工程研究, 2015 (37): 6055-6059.
|
2 |
Haentjens P, Magaziner J, Colón-Emeric CS, et al. Meta-analysis: excess mortality after hip fracture among older women and men [J]. Ann Intern Med, 2010, 152(6): 380-390.
|
3 |
Trpeski S, Kaftandziev I, Kjaev A. The effects of time-to-surgery on mortality in elderly patients following hip fractures [J]. Prilozi, 2013, 34(2): 116-121.
|
4 |
张英泽. 老年股骨颈骨折诊治中的重要问题[J/CD]. 中华老年骨科与康复电子杂志, 2015, 1(1): 6-8.
|
5 |
Ng TM. Levosimendan,a new calcium-sensitizing inotrope for heart failure[J]. Pharmacotherapy, 2004, 24(10): 1366-1384.
|
6 |
Barisin S, Husedzinovic I, Sonicki Z, et al. Levosimendan in off-pump coronary arterybypass [J]. J Cardiovasc Pharmacol, 2004, 44(6): 703-708.
|
7 |
Nijhawan N, Nikolosi AC, Montgomery MW, et al. Levosimendan enhances cardiacperformance after cardiopulmonary bypass: a prospective, randomized placebo-controlled trial [J]. J Cardiovasc Pharmacol, 1999, 34(2): 219-228.
|
8 |
Roche JJ, Wenn RT, Sahota O, et al. Effect of comorbidities and postoperative complications on mortality after hip fracture in elderly people: prospective observational cohort study [J]. BMJ, 2005, 331(7529): 1374.
|
9 |
Toller WG, Metzler H. Acute perioperative heart failure [J]. Curr Opin Anaesthesiol, 2005, 18(2): 129-135.
|
10 |
Hernandez AF, Whellan DJ, Stroud S, et al. Outcomes in heart failure patients after major noncardiac surgery [J]. J Am Coll Cardiol, 2004, 44 (7): 1446-1453.
|
11 |
Romero L, de Virgilio C. Preoperative cardiac risk assessment: an updatedapproach [J]. Arch Surg, 2001, 136 (12): 1370-1376.
|
12 |
Cleland JG, Ghosh J, Freemantle N, et al. Clinical trials update and cumulative meta-analyses from the American College of Cardiology: WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUS-US, RIO-Lipids and cardiac resynchronisation therapy in heart failure [J]. Eur J Heart Fail, 2004, 6(4): 501-508.
|
13 |
Delaney A, Bradford C, Mccaffrey J, et al. Levosimendan for the treatment of acute severe heart failure: a meta-analysis of randomised controlled trials [J]. Int J Cardiol, 2010, 138(3): 281-289.
|
14 |
Toller W, Heringlake M, Guarracino F, et al. Preoperative and perioperative use of levosimendan in cardiac surgery: European expert opinion [J]. Int J Cardiol, 2015, 184: 323-336.
|
15 |
Nieminen MS, Fruhwald S, Heunks LM, et al. Levosimendan: current data, clinical use and future development [J]. Heart Lung Vessel, 2013, 5(4): 227-245.
|
16 |
Elahi MM, Lam J, Asopa S, et al. Levosimendan versus an intra-aortic balloon pump in adult cardiac surgery patients with low cardiac output [J]. J Cardiothorac Vasc Anesth, 2011, 25(6): 1154-1162.
|
17 |
De Hert SG, Lorsomradee S, Cromheecke S, et al. The effects of levosimendan in cardiac surgery patients with poor left ventricular function [J]. Anesth Analg, 2007, 104 (4): 766-773.
|
18 |
Ponschab M, Hochmair N, Ghazwinian N, et al. Levosimendan infusion improves haemodynamics in elderly heart failure patients undergoing urgent hip fracture repair [J]. Eur J Anaesthesiol, 2008, 25(8): 627-633.
|
19 |
Merlo M, Pyxaras SA, Pinamonti B, et al. Prevalence and prognostic significance of left ventricular reverse remodeling in dilated cardiomyopathy receiving tailored medical treatment [J]. J Am Coll Cardiol, 2011, 57(13): 1468-1476.
|
20 |
Akao M, Ohler A, O’Rourke B, et al. Mitochondrial ATP-senstive potassium channels inhibit apoptosisinduced by oxidative stress in cardiac cell [J]. Circ Res, 2001, 88(12): 1267-1275.
|